Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti‐CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

Authors:

Abstract
No abstract available
Funding Information
  • TG Therapeutics